Clinical Outcomes and Patient Satisfaction With Velnez Versus Nasopore in Nasal Surgery
A Prospective, Open-Labelled, Single-Center, Two-Arm, Randomized Clinical Study to Compare Patient Satisfaction and Clinical Outcome Associated With Two Nasal Packs (VELNEZ Vs NASOPORE) in Nasal Surgery.
This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty.
The study addressed two core questions: whether VELNEZ offered superior haemorrhage control and faster biodegradation, and whether it reduced postoperative pain, fibrosis, adhesion, and discomfort compared to NASOPORE.
Participants were randomised to receive either packing material following surgery. They were monitored on the day of surgery for haemostasis and device performance, then followed up with clinical and endoscopic assessments - including pain scoring and adverse event tracking - through Day 90.
調査の概要
詳細な説明
This study was a prospective, randomised, open-label, single-centre, two-arm parallel clinical investigation conducted in a post-market setting. It was designed to evaluate and compare the clinical performance of two biodegradable nasal packing materials - VELNEZ and NASOPORE - following routine nasal surgical procedures under real-world conditions.
Rationale and background Nasal packing is routinely employed after septoplasty, FESS, and turbinoplasty to achieve haemostasis, support mucosal healing, and prevent postoperative complications including adhesions and septal haematoma. Conventional non-absorbable packing materials, while effective for haemostasis, are associated with significant patient discomfort, pain at removal, mucosal trauma, and risk of delayed healing. Biodegradable alternatives were developed to address these limitations by obviating the need for mechanical removal and providing a more favourable postoperative environment.
Investigational devices VELNEZ is a biodegradable composite nasal packing material comprising gelatin, chitosan, polyvinyl alcohol, and psyllium husk. Following placement, it was designed to fragment and gradually dissolve within the nasal cavity over several days. Its composition was intended to deliver effective haemostasis, physically separate mucosal surfaces to reduce adhesion formation, and support tissue regeneration - all without requiring removal, thereby minimising procedure-related trauma and improving patient tolerability.
NASOPORE is a biosynthetic, biodegradable polyurethane foam with established clinical use. Its hydrophilic properties allowed it to absorb fluids and conform to the contours of the nasal cavity, providing mechanical support and haemostatic function. Degradation occurred through fragmentation over time, though the rate and completeness of dissolution varied across patients.
Study design and randomisation Participants were assigned in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing immediately following surgery. Randomisation was performed to minimise selection bias. Given the physical and visual differences between the two materials, blinding of investigators and participants was not feasible; the study was therefore conducted in an open-label manner.
Clinical assessments and follow-up
Assessments were conducted perioperatively and at scheduled postoperative visits through the final follow-up at Day 90. The evaluation framework covered the following domains:
Device performance: Ease of placement, conformability to nasal anatomy, and haemostatic effectiveness were assessed perioperatively. Degradation profile was monitored clinically at each follow-up; irrigation or manual intervention was performed where incomplete dissolution was observed.
Mucosal and structural healing: Endoscopic examination of the surgical site was performed at applicable visits to evaluate mucosal condition, presence of oedema, secretions, fibrosis, scar formation, and adhesion development. Any pressure-related discomfort or structural changes were documented.
Patient-reported outcomes: Symptom burden and quality of life were assessed using the Sino-Nasal Outcome Test (SNOT-22), a validated instrument for sinonasal conditions. Pain and tolerability were evaluated using standardised pain assessment scales at defined time points.
Safety monitoring: Adverse events and serious adverse events were recorded throughout the study. Device-related complications - including infection, hypersensitivity reactions, and signs of delayed healing - were specifically monitored. Vital signs, physical examinations, and laboratory evaluations were conducted per routine clinical practice.
Statistical approach Continuous variables were summarised using descriptive statistics and compared between groups using parametric or non-parametric tests, selected based on data distribution. Categorical variables were analysed using Chi-square or Fisher's exact test, as appropriate. All analyses were conducted at a two-sided significance level.
Ethical and regulatory conduct The study was conducted in accordance with Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki. Institutional Ethics Committee approval was obtained prior to initiation. All participants provided written informed consent before enrolment.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Selangor
-
Sungai Buloh、Selangor、マレーシア、47000
- Hospital Al-Sultan Abdullah, Universiti Teknologi MARA, Jalan Hospital, UiTM Sungai Buloh Campus
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Participants eligible for the use of a nasal pack (either VELNEZ or Nasopore) in routine clinical practice after a planned nasal surgery.
- Male and female in the age group of 18 to 70 years. (Both Included)
- Participants or their LAR who can provide informed consent form in writing.
- Participants who allow their study data to be collected at pre-defined follow-up period.
Exclusion Criteria:
Participants who are unable to be treated with VELNEZ, or Nasopore nasal pack in routine clinical practice after a planned surgery.
- Participant's/ legal guardian (LAR) who cannot provide informed Consent written.
- Participant unwilling or unable to comply with the postoperative visits necessary for data collection.
- Participant with an active infection at the surgery site.
- Participant with a history of asthma.
- Pregnant or lactating Females
- Participant who are on aspirin or anti-platelet drugs therapy.
- Participant positive for HIV, HCV, VDRL, HBs Ag.
- Participant who is allergic (Hypersensitive) to any of the ingredients of the nasal packs.
- Participant with bleeding disorders.
- Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g., a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm 1: VELNEZ Nasal Pack
Participants undergoing planned nasal surgery received the VELNEZ biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice.
The device was intended to provide haemostasis, support mucosal healing, and reduce postoperative complication
|
VELNEZ is a biodegradable composite nasal packing material composed of gelatin, chitosan, polyvinyl alcohol, and psyllium husk.
It is designed to fragment and degrade within the nasal cavity after app
他の名前:
|
|
アクティブコンパレータ:Arm 2: NASOPORE Nasal Pack
Participants undergoing planned nasal surgery received the NASOPORE biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice.
The device was intended to provide haemostasis and structural support within the nasal cavity during the healing process.
|
NASOPORE is a biosynthetic biodegradable polyurethane foam nasal packing material.
It absorbs fluids, conforms to the nasal cavity, and gradually fragments over time.
The device is used for postoperative bleeding control, support of nasal structures, and facilitation of healing following nasal surgery.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical Success of Nasal Pack
時間枠:Up to Day 90 post-surgery
|
Proportion of participants achieved successful clinical outcome defined as complete degradation of the nasal pack within 7 days without device-related adverse events, along with acceptable levels of fibrosis and scar formation, absence of moderate to severe postoperative pain, and no significant breathing discomfort due to pressure effect
|
Up to Day 90 post-surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Haemorrhage Control
時間枠:Day 0 (Intraoperative)
|
Time (in minutes) from application of the nasal pack at completion of surgery to achievement of complete haemostasis, as assessed by the operating surgeon
|
Day 0 (Intraoperative)
|
|
Adhesion Formation (Endoscopic Assessment)
時間枠:Up to Day 90 post-surgery on post surgery follow up visits
|
Incidence and severity of nasal adhesions assessed using endoscopic examination during follow-up visits.
|
Up to Day 90 post-surgery on post surgery follow up visits
|
|
Endoscopic Healing Assessment
時間枠:From Day 7 to Day 90 post-surgery
|
Assessment of nasal mucosal healing based on endoscopic findings including mucosal oedema, nasal secretions, and presence of polyps during follow-up visits
|
From Day 7 to Day 90 post-surgery
|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:From Day 0 to Day 90 post-surgery
|
Number and proportion of participants experiencing adverse events, serious adverse events, or device-related complications during the study period.
|
From Day 0 to Day 90 post-surgery
|
|
Postoperative Pain Assessment using Visual Analogue Scale (VAS)
時間枠:From Day 0 to Day 14 post-nasal surgery
|
Patient-reported pain levels will be assessed using the Visual Analogue Scale (VAS), a 10 cm horizontal line anchored by "no pain" (score = 0) and "worst imaginable pain" (score = 10).
The total score ranges from 0 to 10. Higher scores indicate greater pain intensity and worse outcome (lower tolerability of the nasal pack).
|
From Day 0 to Day 14 post-nasal surgery
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Abdul Azim Al-Abrar Ahmad Kailani、Universiti Teknologi MARA (UiTM), Selangor, Malaysia
- スタディディレクター:Mogana S Rajagopal、UCSI University, Kuala Lumpur, Malaysia
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- DMPL/CIP-002-2024/CT/VN
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。